Yan Su

978 citations
58 papers · 462 indexed · h-index 12
Topics
Neuroblastoma Research and Treatments (22 papers)Glioma Diagnosis and Treatment (9 papers)Cancer, Hypoxia, and Metabolism (8 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONEScientific Reports
Partner nations
ChinaUnited StatesRussia

In The Last Decade

Yan Su

51 papers receiving 456 citations

Peers

Yan Su
Comparison fields: 5 of 63
  • Neurology 152
  • Molecular Biology 114
  • Cancer Research 109
  • Hematology 103
  • Genetics 97
Replace Sabela Bobillo with:
Sabela Bobillo Spain
Akihiro Kitadate Japan
Su Y. Kim United States
Dima El‐Sharkawi United Kingdom
Sharathkumar Bhagavathi United States
Antonio Acquaviva Italy
Pascale Halle France
F. Ong Netherlands
Parth Desai United States
J.P. Vannier France
Yan Su relative to Sabela Bobillo Spain Sabela Bobillo's profile →
Citations per field
00.5×10×15×18×
Sabela Bobillo · 1×
Citations per year

Countries citing papers authored by Yan Su

Since Specialization
Citations

This map shows the geographic impact of Yan Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Su more than expected).

Fields of papers citing papers by Yan Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Su. The network helps show where Yan Su may publish in the future.

Co-authorship network of co-authors of Yan Su

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Su. A scholar is included among the top collaborators of Yan Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Su. Yan Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 0
3 0
4 7
5 2
6 1
7 13
8 1
9 2
10 26
11 4
12 0
13 3
14 1
15 6
16 17
17 0
18 1
19
[Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature].
2
20 10

About Yan Su

Yan Su is a scholar working on Neurology, Genetics and Cancer Research, having authored 58 papers that have together received 462 indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (22 papers), Glioma Diagnosis and Treatment (9 papers) and Cancer, Hypoxia, and Metabolism (8 papers). The work is most often cited by research in Neurology (152 citations), Hematology (103 citations) and Genetics (97 citations). Yan Su has collaborated with scholars based in China, United States and Russia. Frequent co-authors include Runhui Wu, Xiaoli Ma, K. H. Luke, Junting Zhang, Na Zhang, Xinyi Wu, M.‐C. Poon, Zhen Xing, Dairong Cao and Chao Duan. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026